(2S,3S,4R,5R)-2-(4-氨基-5H-吡咯并[3,2-D]嘧啶-7-基)-5-(羟基甲基)-3,4-吡咯烷二醇单盐酸盐
(2S,3S,4R,5R)-2-(4-氨基-5H-吡咯并[3,2-D]嘧啶-7-基)-5-(羟基甲基)-3,4-吡咯烷二醇单盐酸盐
![(2S,3S,4R,5R)-2-(4-氨基-5H-吡咯并[3,2-D]嘧啶-7-基)-5-(羟基甲基)-3,4-吡咯烷二醇单盐酸盐 结构式](https://img.chemicalbook.com/CAS/20180906/GIF/222631-44-9.gif)
(2S,3S,4R,5R)-2-(4-氨基-5H-吡咯并[3,2-D]嘧啶-7-基)-5-(羟基甲基)-3,4-吡咯烷二醇单盐酸盐 性质
| 储存条件 | Store at -20°C |
|---|---|
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
| 水溶解性 | Water : ≥ 41 mg/mL (135.88 mM) |
(2S,3S,4R,5R)-2-(4-氨基-5H-吡咯并[3,2-D]嘧啶-7-基)-5-(羟基甲基)-3,4-吡咯烷二醇单盐酸盐 用途与合成方法
RdRp inhibitor
Cellular kinases phosphorylate Galidesivir (BCX4430) hydrochloride to a triphosphate that mimics ATP; viral RNA polymerases incorporate the drug's monophosphate nucleotide into the growing RNA chain, causing premature chain termination.
Galidesivir hydrochloride effectively inhibits the infection of Vero cells with YFV. The EC
50
determined by the neutral red uptake assay is 8.3 μg/ml (24.5 μM).
Galidesivir (BCX4430) hydrochloride is active after intramuscular, intraperitoneal, and oral administration in a variety of experimental infections. In nonclinical studies involving lethal infections with Ebola virus, Marburg virus, Rift Valley fever virus, and Yellow Fever virus, Galidesivir hydrochloride has demonstrated pronounced efficacy.
Galidesivir hydrochloride (4 mg/kg; i.p.; twice daily for 7 days) is effectively in a hamster model of yellow fever (YF).
| Animal Model: | Female Syrian golden hamsters (hamsters infected with YF virus) |
| Dosage: | 4 mg/kg of body weight |
| Administration: | I.p.; twice daily for 7 days |
| Result: | Significantly improved the survival of hamsters infected with YFV. |
(2S,3S,4R,5R)-2-(4-氨基-5H-吡咯并[3,2-D]嘧啶-7-基)-5-(羟基甲基)-3,4-吡咯烷二醇单盐酸盐 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-11-08 | HY-18649A | (2S,3S,4R,5R)-2-(4-氨基-5H-吡咯并[3,2-D]嘧啶-7-基)-5-(羟基甲基)-3,4-吡咯烷二醇单盐酸盐 | 222631-44-9 | 1mg | 2000 |
| 2024-11-08 | HY-18649A | (2S,3S,4R,5R)-2-(4-氨基-5H-吡咯并[3,2-D]嘧啶-7-基)-5-(羟基甲基)-3,4-吡咯烷二醇单盐酸盐 | 222631-44-9 | 5mg | 6000 |
